- Evonik launches EUDRACAP™ functional, ready-to-fill capsules on commercial scale
- Latest system solution based on technology platform for oral advanced drug delivery
- EUDRACAP™ is suitable from early drug development stages through commercial scale using sensitive molecules, including biologicals
Essen, Germany. On 2 June, Evonik launches the EUDRACAP™ platform of easy-to-handle capsules to help the pharmaceutical industry accelerate speed to market for complex oral drug products in early development stages. EUDRACAP™ enteric is the first product of theplatform to become commercially available. This enteric coated pre-locked capsule gives pharmaceutical companies access to a capsule that can optimize gastric resistance, boost intestinal absorption and enhance bioavailability.
EUDRACAP™ is Evonik’s latest system solution built on the company’s unique technology platform for advanced drug delivery. “With the help of EUDRACAP™, we expect strong growth within our innovation growth field Healthcare Solutions,” says Paul Spencer, head of product line Drug Delivery & Medical Device Solutions at Evonik’s Health Care business line. “EUDRACAP™ will foster our position as a fully integrated CDMO along the entire pharmaceutical value chain.”
The new EUDRACAP™ platform leverages Evonik’s established EUDRAGIT® functional coatings to optimize the release profile of oral drug products. The coated HPMC (hydroxypropyl methyl cellulose) capsules are particularly suited to protect sensitive active pharmaceutical ingredients from moisture and gastric acid.
Oral drugs are being developed rapidly and there is new emphasis on those using mRNA or targeting the microbiome. This has created a great demand in the pharmaceutical industry for ways to increase the number of sensitive molecules in drug product portfolios.
“EUDRACAP™ is our answer to many of the challenges innovators in the pharmaceutical industry are facing when pioneering oral drug products,” says Dr. Axel Schröder, head of Global Business Segment Oral Drug Delivery Solutions at Evonik Health Care.
In addition to EUDRACAP™ enteric, the EUDRACAP™ Select line provides tailor-made CDMO (Contract Development and Manufacturing Organization) services for customer requirements including a range of sizes, colors, and customized release profiles.
“We can help reduce risk and get the finished dosage form in the hands of our customers for clinical and commercial use as fast as possible,” said Dr. Bettina Hölzer, Senior Project Manager Strategic Marketing Oral Drug Delivery Solutions at Evonik Health Care. With EUDRACAP™, customers can tap into Evonik’s expertise across application areas such as colonic delivery, microbiome delivery, personalized dosage forms and bioavailability enhancement.
EUDRACAP™ is the latest in a portfolio of product innovations launched by Evonik’s Health Care business over the past few years. In 2020, Evonik began marketing EUDRATEC® Fasteric, an advanced oral drug delivery technology that provides enteric protection followed by rapid, homogeneous release for effective targeting of the upper small intestine.
Evonik Health Care, which is part of the Nutrition & Care division of Evonik, is one of the world’s leading CDMOs for complex oral and parenteral drug products that require advanced drug delivery solutions. It is also one of the world’s largest suppliers of active pharmaceutical ingredients (APIs), amino acids, cell culture ingredients, medical device excipients and leading global CMO (Contract Manufacturing Organization) for APIs and intermediates.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.
Asia Pacific is a strong driving force of the global economy and an important source of innovation. Consequently Evonik endeavors to further grow its business in the region. Sales reached €2.84 billion in 2020 and the company employs over 5,000 people at more than 50 production sites in Asia Pacific. In Taiwan, we now employ over 200 employees which including 1 office based in Taipei and 1 production site based in Taoyuan.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around three billion euros in 2020 with about 5,300 employees.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.